Multiple myeloma (MM) is an incurable plasma cell malignancies despite the advent of numerously new drugs. Survival was poor particularly for high risk patients such as R-ISS stage III. The preliminary data from our center showed that the median PFS after auto-HSCT was 24 months for patients with R-ISS III stage, while 17 months for patients that achieved PR or less after induction. Chimeric antigen receptor (CAR)-transduced T cells is a promising strategy for cancer immunotherapy. Our previous study showed good response for RRMM patients after CD19 and BCMA-specific CART therapy without severe CRS and other deadly side effects. To improve the survival of high risk patients,this study was designed to observe the safety and efficacy of combined infusion of CD19 and BCMA-specific CART cells after autologous transplantation (SZ-MM-CART02 study, NCT 03455972). 

Tandom autologous transplantation and combined infusion of CART-19 and CART-BCMA cells could be another choice of consolidation treatment for high risk MM patients. Toxicities to date including CRS and organ function impairment seemed to be mild and reversable. It is worthy of further study to compare DFS, OS between single autologous transplantation and tandom transplantation with CART therapy. Immune environment in high risk patients with multiple myelomaI remodelled by auto-HSCT may contribute to more rapid expansion of CART cells than that in RRMM patients, suggesting that the extent of CART expansion depends more than tumor burden.

Authors:

Xiaolan Shi, Lingzhi Yan, Jingjing Shang, Su Qu, Liqing Kang, Jin Zhou, Song Jin, Weiqin Yao, Ying Yao, Shuang Yan, Yong Liu, Guanghua Chen, Ziling Zhu, Huirong Chang, Depei Wu, MD, PhD, Lei Yu and ChengCheng Fu


1009 Tandom Autologous Transplantation and Combined Infusion of CD19 and Bcma-Specific Chimeric Antigen Receptor T Cells for High Risk MM: Initial Safety and Efficacy Report from a Clinical Pilot Study

 


ABOUT CHENGCHENG FU, MD

Dr. ChengCheng Fu is affiliated with the Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou, China.

Previous Post
Preliminary Results from a Phase I Study of Isatuximab in Combination with Bortezomib, Lenalidomide, Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Non-Eligible for Transplant
Next Post
Phase 2 Randomized Study of Daratumumab, Bortezomib, Lenalidomide, and Dex Vs. Vrd in Patients with Newly Diagnosed Multiple Myeloma

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.